Cyclo Historical Balance Sheet

CYTH Stock

USD 0.73 0.03 4.29%

Trend analysis of Cyclo Therapeutics balance sheet accounts such as Short Long Term Debt Total of 1.2 M, Total Current Liabilities of 8.9 M or Total Stockholder Equity of 2.6 M provides information on Cyclo Therapeutics' total assets, liabilities, and equity, which is the actual value of Cyclo Therapeutics to its prevalent stockholders. By breaking down trends over time using Cyclo Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Cyclo Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cyclo Therapeutics is a good buy for the upcoming year.

Cyclo Therapeutics Inventory

250,738

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

About Cyclo Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Cyclo Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Cyclo Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cyclo Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cyclo currently owns. An asset can also be divided into two categories, current and non-current.

Cyclo Therapeutics Balance Sheet Chart

As of now, Cyclo Therapeutics' Accounts Payable is increasing as compared to previous years. The Cyclo Therapeutics' current Cash is estimated to increase to about 9.7 M, while Total Stockholder Equity is projected to decrease to under 2.6 M.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity Accounts Payable Other Current Assets

Total Assets

Total assets refers to the total amount of Cyclo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cyclo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Cyclo Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Cyclo Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Accounts Payable

An accounting item on the balance sheet that represents Cyclo Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cyclo Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from Cyclo Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Cyclo Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.As of now, Cyclo Therapeutics' Accounts Payable is increasing as compared to previous years. The Cyclo Therapeutics' current Cash is estimated to increase to about 9.7 M, while Total Stockholder Equity is projected to decrease to under 2.6 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	171.0K	1.0M	1.2M	1.2M
Total Assets	19.5M	4.2M	13.2M	13.9M

Short Long Term Debt Total Total Assets

Cyclo Therapeutics balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Current Liab	Short Term Investments	Current Deferred Revenue
Total Assets		0.15	0.74	0.85	-0.22	-0.96	-0.71	0.81	0.98	-0.28	-0.35	0.98	0.68	0.64	-0.23	-0.16	0.53	0.79	0.73	0.99	0.4	-0.28	-0.42	0.49	-0.3	-0.52
Short Long Term Debt Total	0.15		0.41	-0.15	0.61	0.11	-0.39	0.14	-0.03	0.57	0.31	-0.03	-0.32	0.58	0.41	-0.14	0.45	0.37	0.47	0.04	0.76	-0.21	-0.37	-0.54	-0.23	0.3
Total Current Liabilities	0.74	0.41		0.29	-0.27	-0.64	-0.95	0.94	0.68	-0.34	-0.48	0.68	0.25	0.94	-0.07	-0.2	0.74	0.95	0.99	0.75	0.79	-0.23	-0.18	0.33	-0.27	-0.6
Total Stockholder Equity	0.85	-0.15	0.29		-0.15	-0.89	-0.3	0.45	0.88	-0.19	-0.19	0.88	0.79	0.18	-0.26	-0.04	0.2	0.4	0.28	0.84	-0.04	-0.23	-0.43	0.5	-0.23	-0.33
Property Plant And Equipment Net	-0.22	0.61	-0.27	-0.15		0.42	0.39	-0.49	-0.35	0.99	0.73	-0.35	-0.35	-0.17	0.03	0.12	-0.35	-0.38	-0.22	-0.36	0.05	-0.12	-0.09	-0.68	-0.12	0.85
Net Debt	-0.96	0.11	-0.64	-0.89	0.42		0.63	-0.79	-0.99	0.47	0.46	-0.99	-0.74	-0.5	0.28	0.16	-0.45	-0.71	-0.62	-0.98	-0.22	0.2	0.37	-0.65	0.22	0.63
Retained Earnings	-0.71	-0.39	-0.95	-0.3	0.39	0.63		-0.91	-0.66	0.46	0.56	-0.66	-0.3	-0.95	-0.17	0.23	-0.9	-0.99	-0.94	-0.74	-0.82	0.24	0.29	-0.35	0.28	0.7
Accounts Payable	0.81	0.14	0.94	0.45	-0.49	-0.79	-0.91		0.8	-0.55	-0.6	0.8	0.44	0.81	-0.13	-0.26	0.7	0.93	0.93	0.85	0.58	-0.24	-0.13	0.59	-0.27	-0.76
Cash	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8		-0.4	-0.42	1.0	0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	0.6	-0.23	-0.58
Non Current Assets Total	-0.28	0.57	-0.34	-0.19	0.99	0.47	0.46	-0.55	-0.4		0.8	-0.4	-0.36	-0.24	0.03	0.12	-0.41	-0.45	-0.28	-0.42	-0.03	-0.15	-0.04	-0.68	-0.14	0.86
Non Currrent Assets Other	-0.35	0.31	-0.48	-0.19	0.73	0.46	0.56	-0.6	-0.42	0.8		-0.42	-0.25	-0.4	-0.01	0.02	-0.49	-0.55	-0.42	-0.46	-0.28	-0.19	0.03	-0.56	-0.17	0.7
Cash And Short Term Investments	0.98	-0.03	0.68	0.88	-0.35	-0.99	-0.66	0.8	1.0	-0.4	-0.42		0.71	0.55	-0.29	-0.17	0.46	0.74	0.67	0.99	0.28	-0.22	-0.39	0.6	-0.23	-0.58
Net Receivables	0.68	-0.32	0.25	0.79	-0.35	-0.74	-0.3	0.44	0.71	-0.36	-0.25	0.71		0.18	-0.25	-0.07	0.22	0.37	0.23	0.7	-0.14	-0.25	-0.07	0.57	-0.25	-0.46
Common Stock Shares Outstanding	0.64	0.58	0.94	0.18	-0.17	-0.5	-0.95	0.81	0.55	-0.24	-0.4	0.55	0.18		0.1	-0.21	0.81	0.94	0.95	0.64	0.9	-0.18	-0.3	0.1	-0.22	-0.49
Non Current Liabilities Total	-0.23	0.41	-0.07	-0.26	0.03	0.28	-0.17	-0.13	-0.29	0.03	-0.01	-0.29	-0.25	0.1		-0.19	0.56	0.11	-0.06	-0.22	0.34	-0.06	-0.35	-0.23	-0.05	0.0
Inventory	-0.16	-0.14	-0.2	-0.04	0.12	0.16	0.23	-0.26	-0.17	0.12	0.02	-0.17	-0.07	-0.21	-0.19		-0.26	-0.22	-0.27	-0.17	-0.02	-0.43	0.49	-0.08	-0.42	-0.02
Other Current Assets	0.53	0.45	0.74	0.2	-0.35	-0.45	-0.9	0.7	0.46	-0.41	-0.49	0.46	0.22	0.81	0.56	-0.26		0.87	0.73	0.56	0.8	-0.18	-0.41	0.2	-0.2	-0.6
Other Stockholder Equity	0.79	0.37	0.95	0.4	-0.38	-0.71	-0.99	0.93	0.74	-0.45	-0.55	0.74	0.37	0.94	0.11	-0.22	0.87		0.94	0.81	0.79	-0.25	-0.33	0.37	-0.28	-0.7
Total Liab	0.73	0.47	0.99	0.28	-0.22	-0.62	-0.94	0.93	0.67	-0.28	-0.42	0.67	0.23	0.95	-0.06	-0.27	0.73	0.94		0.73	0.79	-0.23	-0.21	0.29	-0.28	-0.55
Total Current Assets	0.99	0.04	0.75	0.84	-0.36	-0.98	-0.74	0.85	0.99	-0.42	-0.46	0.99	0.7	0.64	-0.22	-0.17	0.56	0.81	0.73		0.38	-0.24	-0.39	0.58	-0.26	-0.63
Short Term Debt	0.4	0.76	0.79	-0.04	0.05	-0.22	-0.82	0.58	0.28	-0.03	-0.28	0.28	-0.14	0.9	0.34	-0.02	0.8	0.79	0.79	0.38		-0.18	-0.29	-0.16	-0.22	-0.28
Intangible Assets	-0.28	-0.21	-0.23	-0.23	-0.12	0.2	0.24	-0.24	-0.22	-0.15	-0.19	-0.22	-0.25	-0.18	-0.06	-0.43	-0.18	-0.25	-0.23	-0.24	-0.18		-0.33	-0.24	0.99	0.34
Common Stock	-0.42	-0.37	-0.18	-0.43	-0.09	0.37	0.29	-0.13	-0.39	-0.04	0.03	-0.39	-0.07	-0.3	-0.35	0.49	-0.41	-0.33	-0.21	-0.39	-0.29	-0.33		0.17	-0.31	-0.08
Other Current Liab	0.49	-0.54	0.33	0.5	-0.68	-0.65	-0.35	0.59	0.6	-0.68	-0.56	0.6	0.57	0.1	-0.23	-0.08	0.2	0.37	0.29	0.58	-0.16	-0.24	0.17		-0.24	-0.73
Short Term Investments	-0.3	-0.23	-0.27	-0.23	-0.12	0.22	0.28	-0.27	-0.23	-0.14	-0.17	-0.23	-0.25	-0.22	-0.05	-0.42	-0.2	-0.28	-0.28	-0.26	-0.22	0.99	-0.31	-0.24		0.35
Current Deferred Revenue	-0.52	0.3	-0.6	-0.33	0.85	0.63	0.7	-0.76	-0.58	0.86	0.7	-0.58	-0.46	-0.49	0.0	-0.02	-0.6	-0.7	-0.55	-0.63	-0.28	0.34	-0.08	-0.73	0.35

Click cells to compare fundamentals

Cyclo Therapeutics Account Relationship Matchups

Cyclo Therapeutics balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Total Current Liabilities	3.1M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Stockholder Equity	936.0K	10.5M	15.7M	734.5K	4.8M	2.6M
Property Plant And Equipment Net	64.6K	87.9K	77.2K	56.7K	929.3K	505.7K
Net Debt	(2.7M)	(12.7M)	(16.4M)	(1.5M)	(8.2M)	(7.8M)
Retained Earnings	(25.1M)	(34.1M)	(48.3M)	(63.8M)	(83.9M)	(79.7M)
Accounts Payable	3.1M	3.5M	3.7M	2.2M	4.9M	5.1M
Cash	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Non Current Assets Total	155.2K	137.7K	84.5K	56.7K	929.3K	694.6K
Non Currrent Assets Other	90.6K	49.8K	7.3K	(56.7K)	38.3K	36.4K
Cash And Short Term Investments	2.8M	12.8M	16.6M	1.5M	9.2M	9.7M
Net Receivables	182.5K	111.8K	539.1K	55.0K	122.4K	105.2K
Common Stock Shares Outstanding	1.1M	1.6M	6.4M	8.4M	16.3M	17.1M
Liabilities And Stockholders Equity	4.1M	14.2M	19.5M	4.2M	13.2M	13.9M
Non Current Liabilities Total	36.1K	62.9K	18.0K	3.5M	22.5K	21.4K
Inventory	242.6K	237.9K	227.4K	254.5K	254.4K	250.7K
Other Current Assets	749.2K	854.4K	2.1M	4.6M	2.7M	2.8M
Other Stockholder Equity	26.0M	44.5M	64.0M	64.5M	88.6M	93.0M
Total Liab	3.2M	3.7M	3.8M	3.5M	8.5M	8.9M
Total Current Assets	4.0M	14.1M	19.4M	4.2M	12.3M	12.9M
Common Stock	12.2K	477.0	841.0	849.0	2.9K	3.7K
Net Tangible Assets	936.0K	10.5M	15.7M	734.5K	844.7K	802.5K
Other Assets	129.7K	90.6K	49.8K	7.3K	6.6K	6.2K
Property Plant Equipment	64.6K	87.9K	77.2K	56.7K	65.2K	56.7K
Net Invested Capital	936.0K	10.6M	15.8M	734.5K	4.8M	5.5M
Property Plant And Equipment Gross	64.6K	87.9K	159.3K	158.2K	1.1M	1.1M
Net Working Capital	816.9K	10.4M	15.6M	677.9K	3.9M	5.2M
Capital Stock	12.2K	477.0	841.0	849.0	2.9K	3.5K

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Cyclo Therapeutics is a strong investment it is important to analyze Cyclo Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cyclo Therapeutics' future performance. For an informed investment choice regarding Cyclo Stock, refer to the following important reports:

How To Invest In Cyclo

Details

Is Cyclo Stock a good investment?

Details

What is Cyclo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclo Therapeutics. If investors know Cyclo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.90)

Revenue Per Share

0.046

Quarterly Revenue Growth

0.051

Return On Assets

(2.82)

Return On Equity

(226.64)

The market value of Cyclo Therapeutics is measured differently than its book value, which is the value of Cyclo that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclo Therapeutics' market value can be influenced by many factors that don't directly affect Cyclo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cyclo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Historical Balance Sheet

Cyclo Therapeutics Inventory

250,738

About Cyclo Balance Sheet Analysis

Cyclo Therapeutics Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Accounts Payable

Other Current Assets

Cyclo Therapeutics balance sheet Correlations

Cyclo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cyclo Therapeutics balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.99	Total Current Liabilities
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments

Other Stockholder Equity	- 0.99	Retained Earnings
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Net Debt	- 0.96	Total Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings